Decor Led Candle,Electronic Led Candle,Decorative Led Candles,Led Christmas Tree Candles ZhejiangRuitou International Trade Co., Ltd , https://www.rthouseware.com
Vaccine market gap is huge
The problem of insufficient production capacity of vaccines has plagued China. Shen Xinliang, an analyst at Guojin Securities, said that there is a strong demand in the domestic vaccine market, which will increase by approximately 15% each year in the future. In 2007, the market size will be approximately RMB 3.2 billion. In 2008, the country expanded the scope of its immunization program. The central government also spent 2.5 billion yuan to purchase 14 kinds of vaccines. The demand for vaccines is strong, but the gap is large. For example, in red blood cell vaccine, the demand for 2007 was 63.88 million person-times, while the domestic maximum supply was 18 million person-times, and the gap reached 45.79 million person-times.
"The world vaccine industry has experienced a period of recession in the 1980s and has re-emerged in recent years with impressive vitality. It is in a period of rapid growth," said Dr. Yang Yujing, director of industrial business at the Greater China Life Sciences Department of GE Healthcare. This is driven by a combination vaccine technology innovation. Vaccines are not only targeted at infectious diseases. Major breakthroughs have been made in the development of DNA vaccines, HIV vaccines, cardiovascular disease vaccines and cancer vaccines. The availability of numerous new vaccines has increased the capacity of the global vaccine market by more than 10 times in more than 20 years after 1980, while drug sales have only increased five-fold during the same period.
Chinese and foreign enterprises make effort
In this favorable situation, domestic and foreign companies began to use their own strengths. As early as 2006, Novartis decided to enter the influenza vaccine market. When a reporter asked "If the outbreak of influenza pandemic, the world will fall into a short period of flu vaccine shortage, this will affect the supply of Chinese influenza vaccine", Novartis China president Li Zhenfu said that Novartis will first supply the first batch of influenza vaccine to China The market ensures that there is sufficient vaccine supply in the Chinese market. The ambition of French Sanofi-Aventis for the Chinese vaccine market has continued to increase. The company plans to sell 25 million seasonal influenza vaccines annually in China after its Shenzhen influenza vaccine factory is officially put into operation in 2012. Wyeth, which is known for its powdered milk, plans to market its infant pneumococcal vaccine in China. This will be Wyeth's first vaccine product to be listed in China. "We have started to set up a vaccine market development team." Shen Qilei, Wyeth China market manager of vaccine products, said that Wyeth has completed the clinical trial of the vaccine product and is in the registration stage.
Also due to the optimistic view of the Chinese biopharmaceutical and vaccine market, in 2006 GE Healthcare established the FastTrak Technology Center in Shanghai, which is the first downstream biotechnology center established by a multinational company in China. According to Xia Dawei, China director of FastTrak, GE Healthcare, the FastTrak Technology Center provides biopharmaceutical companies with downstream purification process development and related training and certification. Downstream purification technology is a very complex and necessary step in the development of biopharmaceutical companies in the development of vaccines, insulin, interferon and other biological drugs. Most vaccine companies in China use the technology and processes of GE Healthcare to purify their products. At the same time, GE Healthcare's new generation of disposable biopharmaceutical processing products offers opportunities for companies planning to manufacture new vaccine production equipment, at a lower cost and in a shorter time than traditional production facilities.
“Because of the slow pace of new drug development, more and more traditional pharmaceutical companies have begun to move into biopharmaceuticals. The Chinese biopharmaceutical technology has also been gradually optimistic. We hope these technologies will help Chinese companies develop new biopharmaceutical products.†Xia Dawei It said that the current global biopharmaceutical market has reached US$6.3 billion, but China only accounts for US$60 million, of which the downstream purification market is less than US$20 million. It is precisely because of this, for GE Healthcare, China's purification market has a very broad space for development.
The reporter learned that China's vaccine companies will have doubled-increased market opportunities due to the implementation of the "Expanding National Implementation Plan for Immunization Programs." China Biotechnology Group, Beijing Kexing Biological Products Co., Ltd., Beijing Tiantan Biological Products Co., Ltd., Changchun A number of companies, including Changsheng Biotechnology Co., Ltd., Zhejiang Pukang Biotechnology Co., Ltd., Zhejiang Tianyuan Biopharmaceutical Co., Ltd. and the Institute of Medical Biology, Chinese Academy of Medical Sciences, will gain market growth opportunities. In response, Beijing Tiantan Biological Products Co., Ltd. said that the company plans to build a new factory in Daxing, Beijing, in the next two years to expand its vaccine production capacity. It is reported that at present there are 43 vaccine production enterprises in China, which can produce 41 kinds of vaccines for preventing 26 kinds of infectious diseases. The annual output exceeds 1 billion dose units.
Market demand is booming Chinese and foreign companies to dig up vaccine "treasury"
September-November each year is the best time for immunization of the flu. Since August, domestic and foreign companies have begun to vigorously promote influenza vaccine, and public companies have shown that the domestic vaccine market is developing well.